Management of field change in actinic keratosis

British Journal of Dermatology

Volumn 157, Issue SUPPL. 2, 2007, Pages 21-24

  Vatve, M ^a   Ortonne, J P ^b   Birch Machin, M A ^c   Gupta, G ^a  

^a MONKLANDS HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL OF NICE   (France)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Actinic keratosis; Field cancerization; Field change; Skin cancer; Treatment

Indexed keywords

ANESTHETIC AGENT; CYTOKINE; DICLOFENAC; FLUOROURACIL; HYALURONIC ACID; IMIQUIMOD; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; METHYLAMINOLAEVULENIC ACID; MITOCHONDRIAL DNA; PHOTOSENSITIZING AGENT; PROTEIN P53; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACTINIC KERATOSIS; ANUS CANCER; ARTICLE; BLADDER CANCER; BURNING SENSATION; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER RECURRENCE; CLINICAL TRIAL; CLONAL VARIATION; COLON CANCER; CRYOTHERAPY; DRUG CLEARANCE; DRUG SAFETY; EARLY DIAGNOSIS; ESOPHAGUS CANCER; GENE MUTATION; HISTOCHEMISTRY; HISTOPATHOLOGY; HUMAN; LUNG CANCER; MOLECULAR BIOLOGY; OROPHARYNX CANCER; PAIN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RADIATION EXPOSURE; SECOND CANCER; SKIN CANCER; SKIN CARCINOGENESIS; STOMACH CANCER; TUMOR SUPPRESSOR GENE; ULTRAVIOLET RADIATION; UNSPECIFIED SIDE EFFECT; UPPER GASTROINTESTINAL TRACT; UTERINE CERVIX CANCER;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; HUMANS; KERATOSIS; SKIN NEOPLASMS;

EID: 36549083547     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2007.08268.x     Document Type: Article

References (36)

1. Slaughter DP. The multiplicity of origin of malignant tumors: collective review. Int Abstr Surg 1944 79:89 98.
2. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium. Cancer 1953 6:963 8.
3. Ha PK, Califano JA. The molecular biology of mucosal field cancerization of the head and neck. Crit Rev Oral Biol Med 2003 14:363 9.
4. Braakhuis BJ, Tabor MP, Kummer JA et al. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res 2003 63:1727 30.
5. Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol 2000 42:23 4.
6. Moon TE, Levine N, Cartmel B et al. Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: a randomized, double-blind, controlled trial. Cancer Epidemiol Biomarkers Prev 1997 6:949 56.
7. Uhoda I, Quatresooz P, Pierard-Franchimont C, Pierard GE. Nudging epidermal field cancerogenesis by imiquimod. Dermatology 2003 206:357 60.
8. Carlson JA, Scott D, Wharton J, Sell S. Incidental histopathologic patterns: possible evidence of 'field cancerization' surrounding skin tumours. Am J Dermatopathol 2001 23:494 6.
9. Simon R, Eltze E, Schafer KL et al. Cytogenetic analysis of multifocal bladder cancer supports a monoclonal origin and intraepithelial spread of tumor cells. Cancer Res 2001 61:355 62.
10. Tabor MP, Brakenhoff RH, Ruijter-Schippers HJ et al. Multiple head and neck tumors frequently originate from a single preneoplastic lesion. Am J Pathol 2002 161:1051 60.
11. Kanjilal S, Strom SS, Clayman GL et al. p53 mutations in nonmelanoma skin cancer of the head and neck: molecular evidence for field cancerization. Cancer Res 1995 55:3604 9.
12. Jonason AS, Kunala S, Price GJ et al. Frequent clones of p53-mutated keratinocytes in normal human skin. Proc Natl Acad Sci U S A 1996 93:14025 9.
13. Birch-Machin MA. The role of mitochondria in ageing and carcinogenesis. Clin Exp Dermatol 2006 31:548 52.
14. Birch-Machin MA. Mitochondria and Skin Disease. Clin Exp Dermatol 2000 25:141 6.
15. Durham SE, Krishnan KJ, Betts J, Birch-Machin MA. Mitochondrial DNA damage in non-melanoma skin cancer. Br J Cancer 2003 88:90 5.
16. Eshaghian A, Vleugels RA, Canter JA et al. Mitochondrial DNA deletions serve as biomarkers of aging in the skin, but are typically absent in nonmelanoma skin cancers. J Invest Dermatol 2006 126:336 44.
17. Parr RL, Dakubo GD, Crandall KA et al. Somatic mitochondrial DNA mutations in prostate cancer and normal appearing adjacent glands in comparison to age-matched prostate samples without malignant histology. J Mol Diagn 2006 8:312 9.
18. Braakhuis BJ, Brakenhoff RH, Leemans CR. Second field tumours: a new opportunity for cancer prevention? Oncologist 2005 10:493 500.
19. Stockfleth E, Meyer T, Benninghoff B et al. A randomized, double-blind, vehicle controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. Arch Dermatol 2002 138:1498 502.
20. Stockfleth E, Christophers E, Benninghoff B, Sterry W. Low incidence of new actinic keratoses after topical 5% imiquimod cream treatment: a long-term follow-up study. Arch Dermatol 2004 140:1542.
21. Forschner T, Kravtchenko N, Roewart J. A randomised study of topical 5% imiquimod versus topical 5 fluorouracil versus cryotherapy in actinic keratosis - a comparative study. J Dtsch Dermatol Ges 2006 4:804.
22. Lee PK, Harwell WB, Loven KH et al. Long-term clinical outcomes following treatment of actinic keratosis with imiquimod 5% cream. Dermatol Surg 2005 31:659 64.
23. Schon MP, Schon M. Immune modulation and apoptosis induction: two sides of the antitumoral activity of imiquimod. Apoptosis 2004 9:291 8.
24. Schon M, Bong AB, Drewniok C et al. Tumour-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 2003 95:1138 49.
25. Sullivan TP, Dearaujo T, Vincek V, Berman B. Evaluation of superficial basal cell carcinomas after treatment with imiquimod 5% cream or vehicle for apoptosis and lymphocyte phenotyping. Dermatol Surg 2003 29:1181 6.
26. Vidal D, Matias-Guiu X, Alomar A. Efficacy of imiquimod for the expression of Bcl-2, Ki67, p53 and basal cell carcinoma apoptosis. Br J Dermatol 2004 151:656 62.
27. Alomar A, Bichel J, McRae S. Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head. Br J Dermatol 2007 157:133 41.
28. Jorizzo J, Dinehart S, Matheson R et al. Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J Am Acad Dermatol 2007 57:265 8.
29. Jury CS, Ramraka-Jones VS, Gudi V, Herd RM. A randomized trial of topical 5% 5-fluorouracil (Efudix cream) in the treatment of actinic keratoses comparing daily with weekly treatment. Br J Dermatol 2005 153:808 10.
30. Gupta AK, Davey V, Mcphail H. Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: critical review and meta-analysis of efficacy studies. J Cutan Med Surg 2005 9:209 14.
31. Jorizzo JL. Current and novel treatment options for actinic keratosis. J Cutan Med Surg 2004 8:13 21.
32. Nelson C, Rigel D, Smith S et al. Phase IV, open-label assessment of the treatment of actinic keratosis with 3.0% diclofenac sodium topical gel (Solaraze). J Drugs Dermatol 2004 3:401 7.
33. Pirard D, Vereecken P, Melot C, Heenen M. Three percent diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses: a meta-analysis of the recent studies. Arch Dermatol Res 2005 297:185 90.
34. Morton CA. Methyl aminolevulinate: actinic keratoses and Bowen's disease. Dermatol Clin 2007 25:81 7.
35. Wennberg AM, Schmook T, Keohane S et al. A multicentre study of photodynamic therapy with methyl aminolaevulinate (MAL-PDT) in immunocompromised organ transplant recipients with nonmelanoma skin cancer. Photodermatol Photoimmunol Photomed 2005 21:218.
36. Kim HS, Yoo JY, Cho KH et al. Topical photodynamic therapy using intense pulsed light for treatment of actinic keratosis: clinical and histopathologic evaluation. Dermatol Surg 2005 31:33 6.